What is it about?
The total health care cost for human immunodeficiency virus (HIV) patients has constantly grown in recent years. To date, there is no information about how this trend will behave over the next few years. The aim of the present study is to define a pharmacoeconomic model for the forecast of the costs of a group of chronically treated patients followed over the period 2004–2009.
Featured Image
Why is it important?
The treatment of HIV infection in compliance with the guidelines is also effective from the payer perspective, as it allows a good health condition to be maintained and reduces the need and the costs of hospitalizations.
Perspectives
The finding of a stability of expenditure trend in these subjects, with a forecast extended until 2013, allows policymakers to plan a better allocation of health care resources, by putting new resources toward the treatment of newly diagnosed patients and new strategies of care, such as that of simplification of therapy, and, more importantly, to prevent the spread of the disease
prof pietro previtali
university of pavia
Read the Original
This page is a summary of: Forecast model for the evaluation of economic resources employed in the health care of patients with HIV infection, ClinicoEconomics and Outcomes Research, May 2012, Dove Medical Press,
DOI: 10.2147/ceor.s24845.
You can read the full text:
Contributors
The following have contributed to this page
